Future therapies of wet age-related macular degeneration

Makoto Ishikawa, Daisuke Jin, Yu Sawada, Sanae Abe, Takeshi Yoshitomi

Research output: Contribution to journalReview articlepeer-review

48 Citations (Scopus)


Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population, and the prevalence of the disease increases exponentially with every decade after the age of 50 years. While VEGF inhibitors are promising drugs for treating patients with ocular neovascularization, there are limitations to their potential for improving vision in AMD patients. Thus, future therapies are required to have the potential to improve visual outcomes. This paper will summarize the future strategies and therapeutic targets that are aimed at enhancing the efficacy and duration of effect of antiangiogenic strategies.

Original languageEnglish
Article number138070
JournalJournal of Ophthalmology
Publication statusPublished - 2015 Feb 24


Dive into the research topics of 'Future therapies of wet age-related macular degeneration'. Together they form a unique fingerprint.

Cite this